JACC in a Flash | Electronic Alerts For Managing AS, MR; More
Featured topics and Editors' Picks from all of ACC's JACC Journals.
A monthly dose of the novel drug tonlamarsen significantly reduced plasma angiotensinogen (AGT) levels in patients with uncontrolled hypertension compared with a single dose of the drug followed by a placebo, but its impact on systolic blood pressure (SBP) was less clear, according to results from the KARDINAL trial presented at ACC.26 and simultaneously published in JACC.
Automated electronic clinician notification (ECN) alerts improved the timely evaluation and treatment of patients with severe aortic stenosis (AS) or mitral regurgitation (MR), according to findings from ALERT, presented at ACC.26 and simultaneously published in JACC.
The novel PCSK9 oral inhibitor enlicitide effectively lowered LDL-C in adults being treated with statins, demonstrating a potential role as an add-on option for patients not meeting LDL-C goals, according to the CORALreef AddOn trial presented at ACC.26 and simultaneously published in JACC.
JACC Journals at ACC.26
Access all the simultaneous publications in the JACC Journals from ACC.26.
ACC.26 Hub
Clinical Topics: Dyslipidemia, Prevention, Valvular Heart Disease, Homozygous Familial Hypercholesterolemia, Lipid Metabolism, Nonstatins, Novel Agents, Hypertension, Mitral Regurgitation
Keywords: Cardiology Magazine, ACC Publications, CM-May-2026, ACC Annual Scientific Session, ACC26, New Orleans, Antihypertensive Agents, Angiotensinogen, Blood Pressure, Oligonucleotides, Antisense, Injections, Subcutaneous, Hypertension, Mitral Valve Insufficiency, Aortic Valve Insufficiency, Aortic Valve Stenosis, Quality Control, Patient Care Team, Cholesterol, LDL, Hypercholesterolemia, PCSK9
